HER2 dpADC / Sutro Biopharma - LARVOL DELTA

The HER2-targeting dual-payload antibody-drug conjugate combining a topoisomerase I inhibitor and a microtubule inhibitor demonstrates superior efficacy and overcomes resistance to single-payload ADCs in xenograft models (AACR 2026) - "In in vitro cell killing assays, the dpADC performed better than Enhertu and DAR8 exatecan ADC across multiple tumor cell lines. Even in tumors that were rendered resistant to both payloads, the dpADC treatment was able to achieve substantial tumor regression, demonstrating the potential for benefit in mono payload ADC refractory settings. Overall, these results indicate that Sutro's HER2 dpADC can enhance anti-tumor activity beyond that of single-payload ADCs and can overcome prior treatment-induced resistance in a preclinical setting."

ADC • Preclinical • Oncology • HER-2